The Lancet Oncology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2022
-
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study..
25:1337-1346.
2024
-
Cancer and premature mortality—pushing the frontiers of cancer care.
25:946-947.
2024
-
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
25:463-473.
2024
-
The cost and value of cancer medicines in Ontario, Canada.
25:412-413.
2024
-
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
24:323-334.
2023
-
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
23:1508-1516.
2022
-
Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.
23:1499-1507.
2022
-
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
23:1308-1320.
2022
-
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
23:e334-e347.
2022
-
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
23:382-392.
2022
-
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
23:27-52.
2022
-
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.
22:1507-1517.
2021
-
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
22:1403-1415.
2021
-
The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017 (vol 20, pg 1211, 2019).
22:E347-E347.
2021
-
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
22:1139-1150.
2021
-
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.
22:1023-1033.
2021
-
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
22:620-631.
2021
-
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
22:558-570.
2021
-
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
21:1574-1588.
2020
-
First case of osteosarcoma in a dinosaur: a multimodal diagnosis.
21:1021-1022.
2020
-
First case of osteosarcoma in a dinosaur: a multimodal diagnosis..
21:1021-1022.
2020
-
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial.
21:1066-1076.
2020
-
Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic.
21:759-760.
2020
-
Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
21:685-698.
2020
-
Sustainable care for children with cancer: a Lancet Oncology Commission.
21:e185-e224.
2020
-
2019 international clinical practice guidelines for the treatment of venous thromboembolism – Authors' reply.
20:e656-e656.
2019
-
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
20:1531-1543.
2019
-
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
20:e566-e581.
2019
-
The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017.
20:1211-1225.
2019
-
Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study (vol 19, pg 1569, 2018).
20:E10-E10.
2019
-
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
19:1680-1687.
2018
-
Exercise as part of routine cancer care.
19:e432-e432.
2018
-
Exercise as part of routine cancer care.
19:e433-e436.
2018
-
How economic sanctions compromise cancer care in Iran.
19:e334-e334.
2018
-
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
19:521-536.
2018
-
JAVELIN: avelumab another spear to fight urothelial carcinoma.
19:5-7.
2018
-
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
19:27-39.
2018
-
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply.
18:e709-e710.
2017
-
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
18:1532-1542.
2017
-
Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
18:1523-1531.
2017
-
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
18:1373-1385.
2017
-
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
18:1274-1284.
2017
-
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
18:1049-1060.
2017
-
Measuring value and benefit—a matter of perspective.
18:839-840.
2017
-
Targeted radionuclide therapy in combined-modality regimens.
18:e414-e423.
2017
-
Engaging specialist oncologists in the assessment of oncology drugs in Canada.
18:573-575.
2017
-
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
18:473-485.
2017
-
Access to essential medicines for children with cancer: a joint SIOP-CCI position statement.
18:20-22.
2017
-
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
18:31-41.
2017
-
Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.
17:1363-1373.
2016
-
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer.
17:e452-e466.
2016
-
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.
17:164-173.
2016
-
Prophylactic dexamethasone for radiation-induced bone-pain flare – Authors' reply.
17:e40-e41.
2016
-
Classification of treatment-related mortality in children with cancer: a systematic assessment.
16:e604-e610.
2015
-
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
16:1677-1690.
2015
-
Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial.
16:1463-1472.
2015
-
Developments in paediatric care in Latin America.
16:1401-1403.
2015
-
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
16:1079-1089.
2015
-
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
16:1071-1078.
2015
-
The expanding role of primary care in cancer control.
16:1231-1272.
2015
-
Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis.
16:569-582.
2015
-
Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014.
16:e137-e147.
2015
-
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
16:208-220.
2015
-
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
16:87-97.
2015
-
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
15:1379-1388.
2014
-
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
15:1263-1268.
2014
-
Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.
15:164-171.
2014
-
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
15:59-68.
2014
-
Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies.
14:1009-1019.
2013
-
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
14:769-776.
2013
-
New policies to address the global burden of childhood cancers.
14:e125-e135.
2013
-
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
14:236-243.
2013
-
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
13:275-284.
2012
-
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
13:154-162.
2012
-
Chemotherapy for colorectal cancer.
13:e3-e4.
2012
-
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
12:852-861.
2011
-
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
12:559-567.
2011
-
Sentinel nodes in colorectal cancer: cul-de-sac or clarion call?.
12:515-516.
2011
-
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
11:950-961.
2010
-
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial..
11:950-961.
2010
-
Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies.
11:530-542.
2010
-
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
11:55-65.
2010
-
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
11:21-28.
2010
-
Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors.
7:141-148.
2006
-
NSAID and oesophageal adenocarcinoma: randomised trials needed to correct for bias.
7:7-8.
2006
-
Cancer care: what are the priorities?.
2:636-641.
2001
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)